Dalfaz wed retard pills 10mg №30

Coated tablets

Composition

1 three-layer pill of prolonged action contains:

- Active substances
- Alfuzosin hydrochloride (contained in the second, white layer of the tablet) 10 mg.

- The composition of the first layer of pills Hypromellose, hydrogenated castor oil, ethyl cellulose 20, iron dye yellow oxide (E172), colloidal aqueous silicon dioxide, Magnesium stearate.

- The composition of the second layer of Alfuzosin hydrochloride tablet, mannitol, hypromellose, microcrystalline cellulose, povidone, silicon dioxide, colloidal aqueous, magnesium stearate.

- The composition of the third layer of pills Hypromellose, hydrogenated castor oil, povidone, iron dye yellow oxide (E172), colloidal aqueous silicon dioxide, magnesium stearate.

Packing

In 1 blister 10 tablets. In a cardboard bundle 3 blisters.

Mechanism of action

Dalfaz retard - alpha 1 -adrenoblocker, a derivative of quinazoline. Selectively acting on postsynaptic? 1 -adrenoretseptory. In vitro studies have shown selectivity of alfuzosin for? 1 -adrenoretseptory, located in the prostate gland, in the bottom of the bladder and in the prostate part of the urethra.

As a result of direct effects on the smooth muscles of the tissues of the prostate gland reduces the resistance to urine outflow.

Alfuzosin improves urination parameters, reducing the urethra tone and resistance to outflow from the bladder, and facilitates the emptying of the bladder.

In placebo-controlled studies of alfuzosin in patients with benign prostatic hyperplasia, a significant increase in urine flow rate (Q max) was found, on average, by 30% in patients with Q max? 15 ml / s. This improvement was noted after taking the first dose of the drug. There was also a significant decrease in the resistance to the flow of urine and an increase in the volume of excreted urine; there was a significant decrease in residual urine volume.

Indications and usage

- Treatment of functional symptoms of benign prostatic hyperplasia.
- As an aid when using a catheter for acute urinary retention associated with benign prostatic hyperplasia.

Contraindications

- Orthostatic hypotension.
- Severe abnormal liver function.
- Renal failure severe (QC